Patents by Inventor Christopher R. Tudan
Christopher R. Tudan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110230422Abstract: A use of a composition comprising an SDF-1 peptide having the sequence KGVSLSYR is taught. The composition can be used to purge an ex vivo hematopoietic stem cell culture of cancer cells for engraftment in a mammal by administering the composition to the ex vivo hematopoietic stem cell culture in an effective amount.Type: ApplicationFiled: December 23, 2009Publication date: September 22, 2011Inventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Joanne Cashman, Ian Clark-Lewis, Mary A. Richter, Michael Clark-Lewis, Hassan Salari
-
Publication number: 20110118193Abstract: A use of a composition comprising an SDF-1 peptide having the sequence KGVSLSYR is taught. The composition can be used in the manufacture of a medicament for the treatment of a blood cancer in a mammal by administering the medicament in a therapeutically effective amount.Type: ApplicationFiled: December 23, 2009Publication date: May 19, 2011Inventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Joanne Cashman, Ian Clark-Lewis, Mary A. Richter, Michael Clark-Lewis, Hassan Salari
-
Publication number: 20090192082Abstract: Compositions comprising a peptide consisting of an amino acid sequence derived from a P2G-substituted SDF-1 protein are taught. The amino acid sequence consists of a first sequence consisting of 8 to 17 amino acids from the N-terminal portion of the SDF-1 protein and having a conserved KGVS motif. The amino acid sequences may also consist of one or more optional components selected from the group consisting of a second sequence consisting of 8 to 17 amino acids from the N-terminal portion of the SDF-1 protein and having a conserved KGVS motif, wherein the second sequence is covalently joined to the first sequence with or without a linker; and, a third sequence consisting of LKWIQEYLEKALN, or conservative substitutions thereof, wherein the third sequence is covalently joined to the first sequence with the linker. Methods of increasing multiplication of hematopoietic cells and enhancing proliferation of hematopoietic cells during engraftment are also taught.Type: ApplicationFiled: August 11, 2008Publication date: July 30, 2009Inventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Joanne Cashman, Ian Clark-Lewis, Hassan Salari, Mary A. Richter, Michael Clark-Lewis
-
Patent number: 7435718Abstract: In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication, self-renewal, proliferation or expansion. CXCR4 antagonists may be used therapeutically to stimulate hematopoietic stem/progenitor cell multiplication/self-renewal.Type: GrantFiled: September 20, 2004Date of Patent: October 14, 2008Assignees: Chemokine Therapeutics Corp., The University of British ColumbiaInventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Johanne Cashman, Mary A. Richter, legal representative, Michael Clark-Lewis, legal representative, Hassan Salari, Ian Clark-Lewis
-
Patent number: 7378098Abstract: In accordance with various aspects of the invention, CXCR4 agonists, including SDF-1 polypeptides and SDF-1 polypeptide homologues, may be used in reducing the rate of hematopoietic cell multiplication. Methods of the invention may comprise administration of an effective amount of an CXCR4 agonist to cells selected from the group consisting of hematopoietic stem cells and hematopoietic progenitor cells. Cells may be treated in vitro or in vivo in a patient. A therapeutically effective amount of the CXCR4 agonist may be administered to a patient in need of such treatment. Patients in need of such treatments may include, for example patients requiring bone marrow or peripheral blood stem cell transplantation.Type: GrantFiled: February 26, 2002Date of Patent: May 27, 2008Assignees: The University of British Columbia, Chemokine Therapeutics CorporationInventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Johanne Cashman, Ian Clark-Lewis, Hassan Salari
-
Patent number: 6831101Abstract: In various aspects, the invention provides compounds that bind to one or more RANTES receptors for the treatment of chemokine mediated disease states, such as compounds of formula (I):Type: GrantFiled: November 13, 2001Date of Patent: December 14, 2004Assignee: Chemokine Therapeutics CorporationInventors: Geeta Saxena, Christopher R. Tudan, Ahmed Merzouk, Hassan Salari
-
Patent number: 6706767Abstract: The invention provides therapeutic and biological uses of chemokine-receptor-binding compounds including uses in the treatment of disease states mediated by chemokines. The relevant chemokines may for example be monocyte chemoattractant protein-one (MCP-1) or interleukin-8 (IL-8), and the relevant chemokine receptors may for example be corresponding chemokine receptors (CCR-2, CCR-4, CXCR-1, and CXCR-2). In one aspect, the invention provides for the use of phenanthrene-9,10-dione in the treatment of multiple sclerosis.Type: GrantFiled: January 22, 2001Date of Patent: March 16, 2004Assignee: Chemokine Therapeutics CorporationInventors: Geeta Saxena, Christopher R. Tudan, Hassan Salari
-
Patent number: 6693134Abstract: The invention provides therapeutic and biological uses of chemokine-receptor-binding compounds (including chemokine receptor ligands such as chemokine receptor agonists or antagonists), such as naphthoic acid derivatives, including uses in the treatment of disease states mediated by chemokines. The relevant chemokine may for example be stromal cell-derived factor (SDF)-1, and the relevant chemokine receptors may for example be corresponding chemokine receptor (CXCR-4). In other aspects, the invention provides corresponding pharamaceutical compositions and therapeutic methods. In one aspect, for example, the invention provides for the use of 3-Hydroxy-2-naphthoic acid in the treatment of disease.Type: GrantFiled: November 13, 2001Date of Patent: February 17, 2004Assignee: Chemokine Therapeutics CorporationInventors: Geeta Saxena, Christopher R. Tudan, Ahmed Merzouk, Hassan Salari
-
Publication number: 20030148940Abstract: In accordance with various aspects of the invention, CXCR4 agonists, including SDF-1 polypeptides and SDF-1 polypeptide homologues, may be used in reducing the rate of hematopoietic cell multiplication. Methods of the invention may comprise administration of an effective amount of an CXCR4 agonist to cells selected from the group consisting of hematopoietic stem cells and hematopoietic progenitor cells. Cells may be treated in vitro or in vivo in a patient. A therapeutically effective amount of the CXCR4 agonist may be administered to a patient in need of such treatment. Patients in need of such treatments may include, for example patients requiring bone marrow or peripheral blood stem cell transplantation.Type: ApplicationFiled: February 26, 2002Publication date: August 7, 2003Inventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Johanne Cashman, Ian Clark-Lewis, Hassan Salari
-
Publication number: 20030125380Abstract: In various aspects, the invention provides compounds that bind to one or more RANTES receptors for the treatment of chemokine mediated disease states, such as compounds of formula (I): 1Type: ApplicationFiled: November 13, 2001Publication date: July 3, 2003Inventors: Geeta Saxena, Christopher R. Tudan, Ahmed Merzouk, Hassan Salari
-
Publication number: 20030092674Abstract: In various aspects, the invention provides compounds that bind to one or more RANTES receptors for the treatment of chemokine mediated disease states, such as compounds of formula (I): 1Type: ApplicationFiled: June 14, 2001Publication date: May 15, 2003Inventors: Geeta Saxena, Christopher R. Tudan, Ahmed Merzouk, Hassan Salari
-
Publication number: 20030069265Abstract: The invention provides therapeutic and biological uses of chemokine-receptor-binding compounds (including chemokine receptor ligands such as chemokine receptor agonists or antagonists), such as tricyclic phenanthrene derivatives, including uses in the treatment of disease states mediated by chemokines. The relevant chemokines may for example be monocyte chemoattractant protein-one (MCP-1) or interleukin-8 (IL-8), and the relevant chemokine receptors may for example be corresponding chemokine receptors (CCR-2, CCR-4, CXCR-1, and CXCR-2). In other aspects, the invention provides corresponding pharamaceutical compositions and therapeutic methods. In one aspect, for example, the invention provides for the use of phenanthrene-9,10-dione in the treatment of multiple sclerosis.Type: ApplicationFiled: January 22, 2001Publication date: April 10, 2003Inventors: Geeta Saxena, Christopher R. Tudan, Hassan Salari
-
Publication number: 20030045550Abstract: The invention provides therapeutic and biological uses of chemokine-receptor-binding compounds (including chemokine receptor ligands such as chemokine receptor agonists or antagonists), such as naphthoic acid derivatives, including uses in the treatment of disease states mediated by chemokines. The relevant chemokine may for example be stromal cell-derived factor (SDF)-1, and the relevant chemokine receptors may for example be corresponding chemokine receptor (CXCR-4). In other aspects, the invention provides corresponding pharamaceutical compositions and therapeutic methods. In one aspect, for example, the invention provides for the use of 3-Hydroxy-2-naphthoic acid in the treatment of disease.Type: ApplicationFiled: November 13, 2001Publication date: March 6, 2003Inventors: Geeta Saxena, Christopher R. Tudan, Ahmed Merzouk, Hassan Salari
-
Patent number: 6515001Abstract: The invention provides therapeutic and biological uses of chemokine-receptor-binding compounds (including chemokine receptor ligands such as chemokine receptor agonists or antagonists), such as benzopyrone derivatives, including uses in the treatment of disease states mediated by chemokines. The relevant chemokine may for example be interleukin-8 (IL-8), and the relevant chemokine receptors may for example be corresponding chemokine receptors (CXCR-1 and/or CXCR-2). In other aspects, the invention provides corresponding pharamaceutical compositions and therapeutic methods. In one aspect, for example, the invention provides for the use of [7-[benzopyrone-5′(3′-amino)-thiazole]-phenylalanine-benyl ester in the treatment of disease.Type: GrantFiled: March 5, 2001Date of Patent: February 4, 2003Assignee: Chemokine Therapeutic CorporationInventors: Geeta Saxena, Christopher R. Tudan, Nick Cheng, Hassan Salari
-
Publication number: 20030004136Abstract: The invention provides therapeutic and biological uses of chemokine-receptor-binding compounds (including chemokine receptor ligands such as chemokine receptor agonists or antagonists), such as benzopyrone derivatives, including uses in the treatment of disease states mediated by chemokines. The relevant chemokine may for example be interleukin-8 (IL-8), and the relevant chemokine receptors may for example be corresponding chemokine receptors (CXCR-1 and/or CXCR-2). In other aspects, the invention provides corresponding pharamaceutical compositions and therapeutic methods. In one aspect, for example, the invention provides for the use of [7-[benzopyrone-5′(3′-amino)-thiazole]-phenylalanine-benyl ester in the treatment of disease.Type: ApplicationFiled: November 13, 2001Publication date: January 2, 2003Inventors: Geeta Saxena, Christopher R. Tudan, N. Nick Cheng, Hassan Salari
-
Publication number: 20020165123Abstract: In accordance with various aspects of the invention, CXCR4 agonists, including SDF-1 polypeptides and SDF-1 polypeptide homologues, may be used in reducing the rate of hematopoietic cell multiplication. Methods of the invention may comprise administration of an effective amount of an CXCR4 agonist to cells selected from the group consisting of hematopoietic stem cells and hematopoietic progenitor cells. Cells may be treated in vitro or in vivo in a patient. A therapeutically effective amount of the CXCR4 agonist may be administered to a patient in need of such treatment. Patients in need of such treatments may include, for example patients requiring bone marrow or peripheral blood stem cell transplantation.Type: ApplicationFiled: April 12, 2001Publication date: November 7, 2002Inventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Johanne Cashman, Ian Clark-Lewis, Hassan Salari
-
Publication number: 20020156034Abstract: In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication, self-renewal, proliferation or expansion. CXCR4 antagonists may be used therapeutically to stimulate hematopoietic stem/progenitor cell multiplication/self-renewal.Type: ApplicationFiled: May 9, 2001Publication date: October 24, 2002Inventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Johanne Cashman, Ian Clark-Lewis, Hassan Salari
-
Publication number: 20020123483Abstract: The invention provides therapeutic and biological uses of chemokine-receptor-binding compounds (including chemokine receptor ligands such as chemokine receptor agonists or antagonists), such as benzopyrone derivatives, including uses in the treatment of disease states mediated by chemokines. The relevant chemokine may for example be interleukin-8 (IL-8), and the relevant chemokine receptors may for example be corresponding chemokine receptors (CXCR-1 and/or CXCR-2). In other aspects, the invention provides corresponding pharamaceutical compositions and therapeutic methods. In one aspect, for example, the invention provides for the use of [7-[benzopyrone-5′(3′-amino)-thiazole]-phenylalanine-benyl ester in the treatment of disease.Type: ApplicationFiled: March 5, 2001Publication date: September 5, 2002Inventors: Geeta Saxena, Christopher R. Tudan, Nick Cheng, Hassan Salari